Landscape Capital Management L.L.C. Acquires New Stake in Kenvue Inc. (NYSE:KVUE)

Landscape Capital Management L.L.C. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 26,426 shares of the company’s stock, valued at approximately $611,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. O Shaughnessy Asset Management LLC raised its holdings in shares of Kenvue by 34.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 30,765 shares of the company’s stock valued at $660,000 after purchasing an additional 7,854 shares during the last quarter. Axxcess Wealth Management LLC bought a new stake in Kenvue during the 1st quarter worth about $255,000. Advisors Asset Management Inc. acquired a new position in shares of Kenvue during the 1st quarter worth about $206,000. Lazard Asset Management LLC grew its holdings in shares of Kenvue by 52.4% in the 1st quarter. Lazard Asset Management LLC now owns 828,778 shares of the company’s stock valued at $17,784,000 after acquiring an additional 285,128 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC increased its position in shares of Kenvue by 154.8% in the first quarter. Mount Yale Investment Advisors LLC now owns 27,754 shares of the company’s stock valued at $596,000 after acquiring an additional 16,862 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.0 %

Shares of Kenvue stock opened at $24.08 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.31. The stock has a market cap of $46.17 billion, a PE ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. The firm has a 50-day moving average of $22.84 and a 200-day moving average of $20.86. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.31 earnings per share. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. Finally, Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.